Todd Pettingill
Corporate Officer/Principal bei OMNIAB, INC.
Profil
Todd Pettingill is currently the Vice President of Business Development and Strategy at OmniAb Operations, Inc. and OmniAb, Inc. He previously worked as a Senior Manager of Corporate Development at Ligand Pharmaceuticals, Inc. Mr. Pettingill received his undergraduate degree from Brigham Young University and his MBA from UCLA Anderson School of Management.
Aktive Positionen von Todd Pettingill
Unternehmen | Position | Beginn |
---|---|---|
OMNIAB, INC. | Corporate Officer/Principal | - |
OmniAb Operations, Inc.
OmniAb Operations, Inc. BiotechnologyHealth Technology OmniAb Operations, Inc. operates as a drug discovery company. It provides pharmaceutical industry partners access to antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform includes the Biological Intelligence of its transgenic animals, including OmniRat, OmniChicken and OmniMouse, that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company is headquartered in Emeryville, CA. | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Todd Pettingill
Unternehmen | Position | Ende |
---|---|---|
LIGAND PHARMACEUTICALS INCORPORATED | Investor Relations Contact | - |
Ausbildung von Todd Pettingill
Brigham Young University | Undergraduate Degree |
UCLA Anderson School of Management | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
LIGAND PHARMACEUTICALS INCORPORATED | Health Technology |
OMNIAB, INC. | Commercial Services |
Private Unternehmen | 1 |
---|---|
OmniAb Operations, Inc.
OmniAb Operations, Inc. BiotechnologyHealth Technology OmniAb Operations, Inc. operates as a drug discovery company. It provides pharmaceutical industry partners access to antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform includes the Biological Intelligence of its transgenic animals, including OmniRat, OmniChicken and OmniMouse, that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company is headquartered in Emeryville, CA. | Health Technology |